Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania

Nasser, Ahlam; Hussein, Ally Kassim; Chamba, Clara; Yonazi, Mbonea; Mushi, Rosemary; Schuh, Anna; Luzzatto, Lucio

doi:10.1182/bloodadvances.2020002973

Cited by 16 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, besides the normal metabolites of LAB, imatinib was also detected after fermentation. Imatinib is widely used in the treatment of chronic myeloid leukemia [ 84 ]. However, whether imatinib is produced by L. reuteri fermentation needs further experimental confirmation.…”

Section: Resultsmentioning

confidence: 99%

Effect of Coix Seed Extracts on Growth and Metabolism of Limosilactobacillus reuteri

Yang

Wen

Qin

et al. 2022

Foods

View full text Add to dashboard Cite

Coix seed (Coix lachryma-jobi L.) is an important nourishing food and traditional Chinese medicine. The role of their bioactive constituents in physiology and pharmacology has received considerable scientific attention. However, very little is known about the role of coix seed bioactive components in the growth of Limosilactobacillus reuteri (L. reuteri). This study aimed to evaluate the effects of coix seed extract (CSE) on the growth, acidifying activity, and metabolism of L. reuteri. The results showed that CSE can increase the growth and acidifying activity of L. reuteri compared with the control group. During the stationary phase, the viable bacteria in the medium supplemented with coix seed oil (CSO, 13.72 Log10 CFU/mL), coix polysaccharide (CPO, 12.24 Log10 CFU/mL), and coix protein (CPR, 11.91 Log10 CFU/mL) were significantly higher (p < 0.05) than the control group (MRS, 9.16 Log10 CFU/mL). CSE also enhanced the biosynthesis of lactic acid and acetic acid of L. reuteri. Untargeted metabolomics results indicated that the carbohydrate metabolism, amino acid metabolism, and nucleotide metabolism activities of L. reuteri were increased after adding CSE. Furthermore, CSE increased the accumulation of bioactive metabolites, such as phenyl lactic acid, vitamins, and biotin. Overall, CSE may have prebiotic potential and can be used to culture L. reuteri with high viable bacteria.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of Coix Seed Extracts on Growth and Metabolism of Limosilactobacillus reuteri

Yang

Wen

Qin

et al. 2022

Foods

View full text Add to dashboard Cite

show abstract

“…They found that only 23.4% of CML patients achieved an optimal molecular response and 76.6% of CML patients did not have optimal molecular response after the therapy. They assumed that this condition might be associated with inadequate optimal molecular response after 12 months of therapy are the level of therapeutic toxicity and decreased drug adherence (Nasser et al, 2021). Imatinib can cause side effects including weight gain, fatigue (Jabbour & Kantarjian, 2020), bone and muscle pain, as well as increased creatinine.…”

Section: Resultsmentioning

confidence: 99%

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Santosa

Shidqi

Muslim³

et al. 2022

Med.Lab.Tech.J.

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of the BCR-ABL fusion gene in chronic myeloid leukemia. This condition causes excessive cell proliferation, resulting in an increase in the number of leukocytes. Tyrosine Kinase Inhibitor (TKI) is a first-line therapy that helps reduce the percentage of the BCR-ABL fusion gene in patients with chronic myeloid leukemia. This study was conducted to determine differences in the hematological profiles (hemoglobin levels, leukocyte counts, platelet counts) and molecular BCR-ABL in patients with chronic myeloid leukemia before and after 12 months of tyrosine kinase inhibitors therapy. This analytic observational study was administered using a cross-sectional design to in analyzing the medical records of CML patients who underwent TKI therapy at the Sub Specialist Polyclinic of Internal Medicine Hematology Oncology Ulin Banjarmasin Regional Hospital from March 2021-April 2022. Dependent T-test and McNemar's test were performed in data analysis which results showed that 12 month tyrosine kinase inhibitor therapy could increase the hemoglobin levels, decrease leukocyte counts, platelet counts as well as decreasing the percentage of BCR-ABL gene fusion in patients with chronic myeloid leukemia. In conclusion, significant differences were found in the hematological profiles (p<0.001) and the molecular BCR-ABL (p<0.001) before and after 12 months of tyrosine kinase inhibitor therapy

show abstract

“…However, in the area of health there have been “aid” programmes: for instance, since 2002 the Global Fund has disbursed, in the fight against HIV, tuberculosis and malaria, more than $45 billion, 74% of which went to sub- Saharan Africa ( https://www.theglobalfund.org/en/overview/ ). On a much smaller scale, an example worthy of note is that of imatinib: this drug is made available to patients with chronic myeloid leukaemia (CML) in Tanzania and in other countries through the glivec International’s Patient Assistance Program, established by Novartis and implemented in partnership with the Max Foundation (see ( Nasser et al, 2021 )). A limitation of these approaches is that the choices are made by the “donors”, not by the receivers: as a result we have to say–even though it sounds crude–that for a person in Tanzania it is financially preferable to have HIV disease or CML rather than SCD.…”

Section: Discussionmentioning

confidence: 99%

Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet

Luzzatto

Makani

2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Rare diseases (RD) pose serious challenges in terms of both diagnosis and treatment. Legislation was passed in the US (1983) and in EU (2000) aimed to reverse the previous neglect of RD, by providing incentives for development of “orphan drugs” (OD) for their management. Here we analyse the current situation in Africa with respect to (1) sickle cell disease (SCD), that qualifies as rare in the US and in EU, but is not at all rare in African countries (frequencies up to 1–2%); (2) paroxysmal nocturnal haemoglobinuria (PNH), that is ultra-rare in Africa as everywhere else (estimated <10 per million). SCD can be cured by bone marrow transplantation and recently by gene therapy, but very few African patients have access to these expensive procedures; on the other hand, the disease-ameliorating agent hydroxyurea is not expensive, but still the majority of patients in Africa are not receiving it. For PNH, currently most patients In high income countries are treated with a highly effective OD that costs about $400,000 per year per patient: this is not available in Africa. Thus, the impact of OD legislation has been practically nil in this continent. As members of the medical profession and of the human family, we must aim to remove barriers that are essentially financial: especially since countries with rich economies share a history of having exploited African countries. We call on the Global Fund to supply hydroxyurea for all SCD patients; and we call on companies who produce ODs to donate, for every patient who receives an expensive OD in a high income country, enough of the same drug, at a symbolic price, to treat one patient in Africa.

show abstract

Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania

Cited by 16 publications

References 43 publications

Effect of Coix Seed Extracts on Growth and Metabolism of Limosilactobacillus reuteri

Effect of Coix Seed Extracts on Growth and Metabolism of Limosilactobacillus reuteri

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet

Contact Info

Product

Resources

About